0.18
-0.0165(-8.39%)
Currency In USD
| Previous Close | 0.2 |
| Open | 0.19 |
| Day High | 0.2 |
| Day Low | 0.17 |
| 52-Week High | 1.75 |
| 52-Week Low | 0.17 |
| Volume | 16.36M |
| Average Volume | 5.25M |
| Market Cap | 6.43M |
| PE | 0.09 |
| EPS | 2.06 |
| Moving Average 50 Days | 0.2 |
| Moving Average 200 Days | 0.39 |
| Change | -0.02 |
If you invested $1000 in Theriva Biologics, Inc. (TOVX) 10 years ago, it would be worth $0.02 as of February 21, 2026 at a share price of $0.18. Whereas If you bought $1000 worth of Theriva Biologics, Inc. (TOVX) shares 5 years ago, it would be worth $0.87 as of February 21, 2026 at a share price of $0.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
- Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - Rasayana to assume all responsibility and costs
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturd
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
GlobeNewswire Inc.
Dec 29, 2025 1:00 PM GMT
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size, repeated dosing of VCN-01, and an adaptive desi